Novo Nordisk Delivers Fresh Challenge to Eli Lilly With Ozempic Data

More than 630,000 U.S. adults with type 2 diabetes were included in a real-world analysis examining treatment changes involving semaglutide and tirzepatide, Novo Nordisk (NVO) said Tuesday.The analysis covered patients receiving GLP-1 medicines between January 2018 and September 2025. Researchers c…